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 摘要 
脊髓小腦萎縮症第八型是一種漸進性的神經退化疾病，其致病的
原因是由於染色體 13q21 上的 ATXN8OS  (又稱作 SCA8,或 KLHL1AS)
基因在 3’端外顯子的 CTG 三核苷酸不正常擴增所造成。目前對於此
疾病的詳細致病機轉尚未了解，早期相關文獻指出 ATXN8OS 基因並
不具有轉譯蛋白的功能，而可能是以 anti-sense RNA 影響對應股的
KLHL1 基因表現功能；然而最近文獻指出 ATXN8OS 的反譯股
ATXN8，或許會轉譯出 polyQ 蛋白質，而 polyQ 蛋白質也正是許多型
脊髓小腦萎縮症的致病原因；另外，也有研究指出在 ATXN8OS 基因
上 CTG 三核苷酸擴增區域前，可能具有 IRES 活性，而使得此三核
苷酸擴增轉譯出 polyL 毒性蛋白質。為了更進一步去了解 ATXN8OS
致病的分子機制，我們因而建立了 ATXN8OS 的轉殖小鼠模式。利用
原核胚顯微注射的方法，將人類 ATXN8OS 基因帶有正常範圍(22)及
致病範圍(150)兩種 CTG 擴增的基因片段，並連接了綠螢光報導基
因，藉由 NSE 啟動子表現在小鼠的神經系統，以進一步了解 CTG 擴
增對於小鼠造成的影響。從實驗結果中，我們發現帶有致病 CTG 擴
增的轉殖小鼠，在小腦中有神經受損及缺失的情況發生，此外藉由行
為測試也觀察到小鼠的異常行為，我們同時也將相同的基因架構轉殖
進大鼠嗜鉻細胞瘤細胞株(PC12)，建立離體的模式，藉此平臺可快速
  1觀測 ATXN8OS 過度表現會對於神經細胞所產生的影響；從實驗中我
們也發現到帶有致病範圍 CTG 擴增的細胞，在低血清及神經生長因
子的分化刺激下，比正常的細胞更容易死亡，且其神經分化的能力也
較差，由這些研究結果，我們發現不管 ATXN8OS 過度表現在離體及
活體內均造成神經傷害，這些結果將有利於在相關疾病的基因及藥物
治療研究之應用。 
 
 
 
 
 
 
 
 
 
 
 
 
 
  2Abstract 
Spinocerebellar ataxia type 8 (SCA8) was reported caused by an 
unstable CTG repeat expansion in the 3’ terminal exon of ATXN8OS (also 
named SCA, or KLHL1AS) gene on chromosome 13q21. How the 
trinucleotide expansion causes the disease is not clear now. Some studies 
indicate that ATXN8OS might not encode protein and play an anti-sense 
regulatory role on the sense strand gene, KLHL1. However, a recent study 
indicates that the opposite strand of ATXN8OS, ATXN8, encodes a 
polyglutamine expansion protein, which might explain the 
gain-of-function mutation of SCA8 disease as other 
polyglutamine-mediated SCAs. To further investigate the molecular 
mechanism of SCA8, a transgenic mouse model was established. The 
human ATXN8OS full-length cDNA with 22 or 150 CTG repeats in-frame 
fused with flag-EGFP was used as the transgene and driven by a 
neuron-specific-enolase (NSE) promoter. Our results show that the 
transgenic mice with expanded CTGs have some neuropathologies in the 
cerebella, including the neuronal cell loss and behavior abnormality. To 
have a quick platform to access the ATXN8OS overexpression effect on 
neuronal cell level, we also transfected constructs of ATXN8OS with 22 
or 150 CTG repeats into the rat pheochromocytoma (PC12) cell line. We 
found that cells with expanded 150 CTG repeats were more vulnerable 
and showed reduced neuronal differentiation under low serum and NGF  
condition compared to cells with normal CTG expansion. With these 
models, we could gain some information about the molecular effects 
resulted from overexpression of ATXN8OS in vivo and in vitro, which 
  3should further provide more implications for the therapeutic design of 
SCA8 in the future.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  4Introduction 
 
Spinocerebellar ataxias (SCAs) 
 
The word “ataxia” derived from Greek, refers to “incoordination or 
without order”. In 19th century, this disease has been identified and 
called “Friedreich’s ataxia”, an inherited disease that causes progressive 
damage of the nervous system. The symptoms include gait disturbance, 
speech problems and heart disease. Until year 1983, Dr. Pierre Marie 
noticed that inherited ataxia disease was different from Friedreich's ataxia 
because its onset was much later then Friedreich's ataxia. According to 
pathogenesis, they were classified into two types: early onset-Friedreich's 
ataxia and late onset-Marie's ataxia. Therefore, ataxias at that time were 
roughly divided into Friedreich's ataxia and Marie's ataxia, based on the 
age of onset. 
The ataxias are a complex group of debilitating and often fatal 
neurodegenerative diseases that lead to generalized incoordination of gait, 
speech and limb movements (Currier, 1984; Harding, 1993). The 
spinocerebellar ataxias (SCAs) are a clinically and genetically 
heterogeneous group of dominantly inherited neurodegenerative disorders, 
characterized by prominent ataxia and cerebellar atrophy and 
degeneration of the cerebellum and its connections (Glickstein, 2006; 
Izumi et al., 2003; Juvonen et al., 2002; Koob et al., 1999; Schmahmann 
and Caplan, 2006). Some of these disorders also affect the retina, 
peripheral nerves, the pyramidal and extra pyramidal motor systems, and 
  5cognitive function. Spinal cord, brainstem, basal ganglia, or peripheral 
nervous system are also involved in some of these disorders (Glickstein, 
2006; Izumi et al., 2003; Juvonen et al., 2002; Koob et al., 1999; 
Schmahmann and Caplan, 2006; Zeman et al., 2004).   
SCAs were initially classified according to clinical and 
neuropathological descriptions. Dr. Harding classified autosomal 
dominant cerebellar ataxias (ADCAs) into three types, according to the 
mode of inheritance and the clinical signs. ADCA type І is characterized 
by a progressive cerebellar syndrome, with additional but variable 
associated features of supranuclear ophthalmoplegia, optic atrophy, mild 
dementia, peripheral neuropathy or extrapyramidal dysfunction. SCA1, 
SCA2, SCA3, SCA4, SCA8, SCA12, SCA17, dentatorubral 
pallidoluysian atrophy (DRPLA) and recently defined SCA27 and SCA28 
belong to this type (Flanigan et al., 1996; Imbert et al., 1996; Kawaguchi 
et al., 1994; Orr et al., 1993; Pulst et al., 1996; Sanpei et al., 1996). 
ADCA type II shows cerebellar ataxia accompanied with pigmentary 
macular dystrophy, maybe pathogenesis before 10 years old and only 
SCA7 is included (Del-Favero et al., 1998; Giunti et al., 1999; Harding, 
1993). ADCA type III is a pure cerebellar syndrome and comprises SCA5, 
SCA6, SCA10, SCA11, SCA14, SCA15, SCA22, and SCA26. SCA13 
does not fall within any categories described above (Ranum et al., 1994; 
Worth et al., 1999; Zhuchenko et al., 1997).       
  It has now defined 28 types of SCA. According to clinical 
symptoms, SCA is categorized by radiological point of view, 3 patterns 
of atrophy can be observed: a pure cerebellar atrophy (SCA4, SCA5, 
SCA6, SCA8, SCA9, SCA10, SCA11, SCA14, SCA15, SCA16, SCA18, 
  6SCA21, SCA22), a pattern of olivopontocerebellar atrophy (SCA1, SCA2, 
SCA3, SCA7, SCA13), or a pattern of global cerebral atrophy (SCA12, 
SCA17, SCA19, DRPLA). Most of the SCAs start by a cerebellar atrophy 
which can progress subsequently to extracerebellar structures. 
The prevalence of SCAs is estimated to be 1-4/10000, but it can be 
much higher in some regions because of a founder effect (van de 
Warrenburg et al., 2002). This is the case for SCA2 in Cuba, SCA3 in the 
Azores (Orozco Diaz et al., 1990; Silveira et al., 1998), and SCA10 has 
been reported in Mexico.       
Different SCAs may sometimes have overlapping signs and it is 
difficult to distinguish by clinical symptoms. However, with advance of 
molecular biotechnology, mutation analyses afforded the genetic 
classification of clinical subtypes. SCAs are largely caused by the 
unexpected prolongation of tandem nucleotide repeats. In SCAs due to a 
CAG expansion (SCA1, SCA2, SCA3, SCA6, SCA7, SCA17, and 
DRPLA) associated with expansions of coded CAG repeats translated 
into polyglutamine (polyQ) stretch that adds a toxic protein (David et al., 
1997; Imbert et al., 1996; Kawaguchi et al., 1994; Koide et al., 1994; Orr 
et al., 1993; Pulst et al., 1996; Zhuchenko et al., 1997), and an 
untranslated CTG repeat being found in SCA8 (Koob et al., 1999), the 
promoter CAG repeat expansion in SCA12, SCA10 with expansions in 
intronic ATTCT (Holmes et al., 1999; Matsuura et al., 2000). In addition, 
SCA5, SCA14, and SCA27 have been found caused by missense 
mutations (Brusse et al., 2006; Ikeda et al., 2006; Yabe et al., 2003). 
 
Spinocerebellar ataxia type 8 (SCA8) 
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SCA 8 is an autosomal dominant late-onset neurodegenerative 
disorder, first described in 1999, associated with CTG trinucleotide repeat 
lying on chromosome 13q21 (Koob et al., 1999). SCA8 also is the first 
example of a dominant SCA not caused by a CAG expansion translated 
as a polyQ  tract. Dysarthria, mild aspiration and gait instability are 
commonly the initial symptoms. Exam findings included spastic and 
ataxic dysarthria, nystagmus, limb and gait ataxia, limb spasticity and 
diminished vibration perception, Pyramidal and sensory features have 
been described in around one-third of cases with cognitive features, 
including dementia. One report indicated mother and son of a familiy 
with the SCA 8 expansion, cerebellar ataxia, personality change and a 
dysexecutive syndrome (Stone et al., 2001). A recent study concluded 
that the disorder is associated with deficits of attention, executive 
function and information processing (Lilja et al., 2005; Zeman et al., 
2004). One other research have reported highly variable rates of cognitive 
and behavioural features (Zeman et al., 2004), and with clinical findings, 
magnetic resonance imaging (MRI) showed cerebellar atrophy, and 
cognitive impairments especially those related to attention, information 
processing and executive function (Lilja et al., 2005). The dominant 
inheritance pattern of the large SCA8 kindred is complicated, showing 
reduced penetrance with an extreme maternal penetrance bias (Koob et al., 
1999). 
The SCA8 transcript, containing the CTG expansion, has been 
identified in brain tissue and weakly in lung, kidney, and testis (Benzow 
and Koob, 2002).   
  8With 110~130 CTA/CTG combined repeats in the affected 
individuals, a short polymorphic CTA repeat (1–21 CTAs) precedes the 
major CTG repeat, the sizing of SCA8 alleles has been clarified in 
various populations, with unrelated expanded alleles ranging from 68 to 
800 repeats found in familial and sporadic ataxia patients (Day et al., 
2000; Ikeda et al., 2000; Izumi et al., 2003; Juvonen et al., 2002; Moseley 
et al., 2000; Tazon et al., 2002; Topisirovic et al., 2002). Quoted repeat 
lengths are usually for the CTA/CTG composite. Over 99% of individuals 
in control populations have fewer than 91 CTA/CTG repeats (Zeman et 
al., 2004), the prevalence of repeat expansions in such populations is 
much higher than the prevalence of the disorder, indicating that the 
expansion has a low penetrance and may be best regarded as a risk factor 
for ataxia (Torrens et al., 2008). 
Recent data suggest that bidirectional transcription of ATXN8OS 
(SCA8) occurs, ataxin8 (ATXN8), which encodes a polyQ protein in the 
CAG orientation, and ATXN8OS transcribed to potentially pathogenic 
CUG transcripts. Because both CUG expansion transcripts and polyQ 
expansion proteins are both known to be toxic in other diseases SCA8 
may involve both RNA and protein gain of function mechanisms (Ikeda 
et al., 2008; Moseley et al., 2006; Paulson, 2006).   
  
Heredity of Spinocerebellar ataxia 
 
“Anticipation” refers to the phenomena the disease transmitted to the 
next generation begins at more earlier age. This phenomena is found in 
trinucleotide repeat expansion disease, including myotonic dystrophy, 
  9Huntington’s disease, SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, 
SCA12, SCA17, SCA22, and DRPLA. 
 
SCA8 and KLHL1 
 
In humans, there are three different genes ATXN8, ATXN8OS (SCA8 
or KLHL1AS) and Kelch-like 1 (KLHL1) located in relatively close. The 
genomic organization of the overlapping ATXN8 and ATXN8OS genes 
and  KLHL1 gene is shown in Appendix Fig 3. The SCA8 expansion 
mutation is located within both of the overlapping ATXN8OS and ATXN8 
genes. In contrast, the KLHL1 genes overlap at 5’exon of ATXN8OS, 
approximately 35 kb upstream of the repeat. These three genes are 
summarized as follows: (i) ATXN8, which contains the repeat expansion, 
is transcribed in the CAG direction and encodes a nearly pure polyQ 
expansion protein; (ii) ATXN8OS spans the repeat in the CTG direction 
with the repeat of this highly alternatively spliced and apparently 
non-protein coding gene; (iii) KLHL1 encodes an actin binding protein 
expressed in the central nervous system and does not overlap with the 
repeat (Moseley et al., 2006). Transcripts encoded by both the ATXN8 
and ATXN8OS genes are expressed at low steady-state levels in the 
human central nervous system. Although the SCA8 repeat is not 
conserved in the mouse (Andres et al., 2004; Andres et al., 2003; Benzow 
and Koob, 2002), while there is a mouse homolog of KLHL1 (Klhl1) and 
a much shorter version of the human ATXN8OS gene (Klhl1as), the 
mouse  Klhl1as gene is much simpler with only a single exon and 
conservation with only the 5’ end of the human ATXN8OS (Benzow and 
  10Koob, 2002). 
 
KLHL1 ( kelch like protein 1 ) 
 
KLHL1 protein is actin binding protein, and is homology to 
Drosophila kelch protein. This protein family contains two highly 
conserved signature domains: a BTB/POZ domain involved in protein 
dimerization (Bardwell and Treisman, 1994; Zollman et al., 1994), and 
the actin-binding Kelch domain (Adams et al., 2000). The mammalian 
KLHL1 is a brain-specific cytosolic protein that can form multimers and 
bind actin filaments (Nemes et al., 2000). 
KLHL1 can interact with the α1A subunit of the P/Q-type Ca
2+ 
channel and modulate its function by increasing its current density and 
channel availability for opening, suggesting that KLHL1 can modulate 
calcium channel, process neuronal calcium influx and excitability. 
(Aromolaran et al., 2007). 
 
IRES (internal ribosome entry site) 
 
Initiation of translation often depends on 5’ m
7G cap, which interact 
to 43S ribosome with the cap binding protein eIF4E (Sonenberg, 1994). 
A cap-independent mechanism called IRES was first demonstrated in 
picornaviruses, which lack a 5’ m
7G cap and have long structured 
5’UTRs in their RNA. The presence of an internal ribosome entry site 
(IRES) has been shown in different picornaviruses, such as 
encephalomyocarditis virus (EMCV), human rhinoviruses, and hepatitis 
  11A virus (Jackson et al., 1995). This mechanism requires secondary 
structures that allow ribosomes to bind directly next to the initiator AUG 
and permit translation to start without previous scanning. Recently, IRES 
elements have been found in several cellular mRNAs, and also found in a 
variety of other mammalian genes. 
ATXN8OS was first thought a non-coding gene (Koob et al., 1999), 
but a recent genetic examination revealed that ATXN8OS may encode 
three ORFs, ORF1, ORF2, and ORF3, through IRES mechanism. Among 
them ORF1 is a 102 amino acids, and ORF3 is a 41 amino acids in front 
of a stretch of polyleucine encoded by the CUG repeats. If ATXN8OS 
have the cap-independent IRES activity, these three ORFs maybe 
translated and their pathogenesis need to be further investigated is shown 
in Appendix Fig. 6 (Lin, 2007).     
 
Complete Control
® Inducible Mammalian Expression System 
(Stragagene) 
 
    The ecdysone receptor (EcR) is a member of the 
retinoid-X-receptor (RXR) family of nuclear receptors. In mammalian 
cells, EcR heterodimerizes with RXR and binds to multiple copies of the 
ecdysone-responsive element (EcRE). In the absence of PonA, 
transcription of expression cassette will be shut down. When PonA binds 
to the receptor, the receptor complex activates transcription of an 
interested gene. To avoid pleiotropic interactions with endogenous 
pathways in mammalian host cells, the EcRE recognition sequence was 
modified and renamed as E/GRE; the EcR protein was also modified 
  12(called GEcR, glucocorticoid receptor –EcR fusion proteins) that won’t 
transactivate any host genes, retained the ability to dimerize with RXR 
and activate interested genes in E/GRE cassettes. In Complete Control
® 
Inducible Mammalian Expression System, pERV3 vector was designed 
for GEcR with VP16 activation domain; pEGSH vector was designed for 
E/GRE with PonA-inducible cassette, multiple cloning sites (MCS) for 
inserting the gene of interest, and FLAG epitope.     
 
  13Materials and methods 
 
Transgene construction and SCA8 transgenic mouse generation 
 
  Human full length ATXN8OS cDNAs with 22 or 150 CTG repeats 
fused with flag tag and EGFP reporter gene were used as transgene for 
generation of SCA8 transgenic mice. The ATXN8OS-flag-EGFP was 
driven by NSE promotor, which mainly expresses transgene in neuronal 
cells. The transgene was separated from the plasmid backbone by 
digested with MluI and injected into mouse pronuclei to generate 
transgenic mice. One ATXN8OS-150R transgenic line with FVB genetic 
background was established in our lab (Chen, 2006). The remaining 
ATXN8OS-22R and ATXN8OS-150R with B6 genetic background were 
generated by core facility of Institute of Molecular biology Academia 
Sinica.  
 
Mouse Genotyping   
 
Mouse genomic DNAs were isolated from 0.5 cm length of tail 
biopsy. Tissues were first lysed in tail solution [10 mg/ml proteinase K, 
2% SDS, 5 M NaCl, 0.5 M EDTA (pH 8.0), 1 M Tris (pH 7.4)] at 65℃ 
overnight. The mixture was then mixed with 5 M potassium acetate and 
incubated at 4  for 1 hour followed by centrifugation at 13400 xg at  ℃ 4  ℃
for 30 minutes. The supernatant was transferred to a fresh tube and mixed 
well with ethanol. DNA was precipitated by centrifugation at 13400 xg at 
  144  for 5 ℃  minutes and then rinsed with 70% ethanol. DNA pellet was air 
dried and resuspended with 65  ddH ℃ 2O. Transgenic mice were identified 
using polymerase chain reaction (PCR) with a set of primers localized in 
NSE promotor (forward: 5’-AAT AAG GAG ACG CCT GCT TCC 
CTC-3’), and ATXN8OS cDNA (reverse: 5’-CAT GTC AGG CTC TGG 
GCG AAA AG-3’). The 818 bp fragment product was amplified from the 
PCR by condition: 95 , 1 min ℃ ute for denaturing, 58 (touch down) 1  ℃
minute for primer annealing, 72 1 min ℃ ute for elongation, and 35 cycles 
for total reaction.  
 
Semi-quantitative PCR 
 
To distinguish the homozygous mice from heterozygous mice, we 
used semi-quantitative PCR to analysis mouse genotypes with a forward 
primer (NSE-F: 5’-AAT AAG GAG ACG CCT GCT TCC CTC-3’) and a 
reverse primer (SCA8-R: 5’-CAT GTC AGG CTC TGG GCG AAA 
AG-3’). The 818 bp product was amplified 95℃1 minute for denaturing, 
58  (touch down)  ℃ 1 minute for primer annealing, 72℃1 minute for 
elongation and repeated for 30 cycles. forward primer (β-actin-F: 5’-ATG 
GAT GAC GAT ATC GCT-3’) and a reverse primer (β-actin-R: 5’-ATG 
AGG TAG TCT GTC AGG T-3’). The 1100 bp product was amplified by 
a PCR condition, 95℃1 minute for denaturing, 54   ℃ 1 minute for primer 
annealing, 72℃1 minute for elongation and repeated for 30 cycles. The 
1100 bp β-actin product was used as an internal control for the 
semi-quantitation. Primers of β-actin were 3 times of the genotyping 
primers. 
  15RNA isolation from mouse cerebellum and reverse transcription 
 
RNA isolation from mouse tissue was conducted using Trizol reagent 
(Invitrogen). The procedure was carried out according to the 
manufacturer’s instructions. Trizol reagent 300 µl was added to tissue, 
after pipeting mix, the mixture was centrifuged at 13400 xg at 4°C for 15 
minutes. The supernatant was collected and 60 µl of chloroform was 
added into the supernatant. Samples were vigorously inverted by hand for 
10 times. RNA was then separated form DNA and proteins by 
centrifugation at 13400xg  for 15 minutes at 4°C. Following 
centrifugation, the colorless supernatant was carefully transferred to a 
fresh tube avoiding touch the interface. 150 µl volume of isopropyl 
alcohol was added to the supernatant, following a 10 minutes incubation 
at 4°C RNA was precipitated by centrifuged at 13400xg at 4°C for 10 
minutes. The pellets were rinsed once with 75% ethanol, RNA were air 
dried and dissolved in 65°C RNase-free water. After DNase treatment, 
2μg of RNA was reverse transcribed into cDNA using the SuperScript
TM 
Ш reverse transcriptase (Invitrogen). The SCA8-F1 (5’-TTG AAG ATT 
GCC TTT TCT GAC TCC C -3’) and EGFP-R (5’-ACT CCA GCA GGA 
CCA TGT G -3’) primers were used to amplify cDNA fragments to assess 
the expression of transgene transcripts.   
 
Behavioral  testing    
A.  Rotarod analysis 
 
This task was used to assess motor coordination, balance, and motor 
  16learning. We used a rotrod (UGO 47600) to assess the ability of SCA8 
and wild type mice remaining on a rotating rod as the speed of rotation 
was fixed 25 rpm for 180 seconds. An entire testing process required four 
days (the first two days for training and the last two days for testing), 
three trials per day for each mouse. In each test, the mice were subjected 
to the three trials with a 40 minutes of rest between trials, and the average 
time to fall off the rod was determined and series of testing in coming 
months were completed in two days per month. Series of rotarod analysis 
were processed on mice every four weeks. 
 
B.  Locomotor activity monitoring   
 
Mice were placed in an open field (30 cm x 30 cm x 30 cm black box) 
and allowed to explore the environment for 10 minutes. Using 
Etho-Vision video tracking system, we evaluated distance of horizontal 
movement, movement velocity and rearing frequency of each mouse in 
10 minutes, and collected parameters of 10 minutes for paired-samples T 
test analysis. 
 
Perfusion 
 
    Mice were anesthetized with 2.5% avertin (18 μl/g mouse weights) 
and then perfused with 4% paraformaldehyde. We inserted a 23 3/4 gauge 
needle in the aorta below the renal arteries and started perfusion with 
0.9% normal saline for replacing blood and then exchanged with 4% 
paraformaldehyde until the limbs of mice were found totally rigid. Mouse 
  17brain was then removed and cerebellum was cut and postfixed in 4% 
paraformaldehyde in 1X PBS for 24 hours. The tissues were then 
dehydrated by transferred into 10% sucrose in 1X PBS for 1 hour, 20% 
sucrose in 1X PBS for 2 hours, 30% sucrose in 1X PBS for 48 hours, and 
cut into 30 µm thick in sagittal sections. 
 
Immunohistochemistry (IHC) 
 
The cerebellum sections floating in 1X PBS were prepared for IHC. 
Sections were first washed with 1X PBS 10 minutes for three times. 
Endogenous peroxidase activity of sections was blocked by 3% H2O2 for 
30 minutes. After washed with 1X PBS for twice, nonspecific epitopes of 
sections were then blocked by 4% BSA for 2 hours. Sections were then 
incubated at room temperature with primary antibody diluted with 
blocking solution overnight. After three times wash with 1X PBS for 10 
minutes each, cerebellum sections were incubated with linking reagent 
(DAKO) for 1 hour, washed with 1X PBS two times, and then incubated 
with labeling reagent (DAKO) for 1 hour. After washed with 1X PBS two 
times, immunostainings of sections were performed using DAB 
(diaminobenzidine, DAKO) and substrate for 10 seconds to 3 minutes. 
After washed with 1X PBS for four times, all floating sections were 
mounted on coated slides. After air-dried overnight, slides were ethanol 
dehydrated, and cover slipped for light microscopy. 
 
Western blot analysis 
 
  18Brain tissue was lysed in a RIPA buffer containing 1M Tris (pH 7.5), 
5M NaCl, 0.5M EDTA (pH 8.0), 10% SDS, 10% DOS, and 10% NP40 
supplemented with protease inhibitors. Samples were sonicated and 
determined the protein concentrations using a BCA protein assay kit 
(PIERCE). Samples were incubated at 95°C for 10 minutes and loaded to 
SDS gels. After polyacrylamide gel electrophoresis (PAGE), proteins 
were transferred onto PVDF membrane (Millipore), followed by blocking 
with 5% nonfat skim milk in 1X PBS containing 0.05% Tween20 for 2 
hours. Blots were incubated with primary antibodies 4°C overnight and 
secondary antibodies at room temperature for 1 hour. Secondary 
antibodies were diluted (1:5000) with 3% nonfat skim milk in 1X PBS 
containing 0.05% Tween20. Immunoreactive bands were visualized using 
enhanced chemiluminescence (ECL) reagent (chemiluminescent HRP 
substrate, Millipore).   
 
In-situ hybridization 
 
Expression of mRNAs in cerebellum tissues was determined by 
in-situ hybridization. First, we cut cerebellum tissue into 30 μm sections 
and then incubated slices at 37℃ overnight. We used constructs 
pGEM-T/NSE-ATXN8OS-Flag-EGFP which was establish for generating 
our transgenic mice, and PCR primers, Flag-F (5’- TGA CTA CAA AGA 
CGA TGA CG -3’) and EGFP-R ( 5’- CTT GAA GAA GAT GGT GCG 
-3’) to amplify probe templates. The templates were purified with same 
volume of phenol-chloroform extraction and 2.5X volume 99% ethanol 
  19precipitation. The RNA pellets were then rinsed once with 1 ml 70% 
ethanol, air-dried and dissolved in 65°C RNase-free water. A mixture of 
digoxigenin(DIG)-labeled RNA mix 2 μl, 10×buffer 2 μl, RNase 
inhibitor 1 μl, RNA polymerase 2 μl was added into purified template, 
than RNase-free water was added to a 20 μl of volume. After DNase 
treatment for 30 minutes, the mixture was heated at 65°C for 10 minutes 
to stop DNase activity. 2X volume of 99% ethanol precipitation, then 
pellets were rinsed once with 1 ml 70% ethanol, RNA were air dried and 
dissolved in 65°C RNase-free water. In vitro transcribed 
digoxigenin(DIG)-labeled RNA products used as probes were purified by 
phenol-chloroform extraction and ethanol precipitation. The RNA probe 
was produced using DNA template, RNA polymerase (Roche) and DIG 
RNA labeling Mix (Roche), DIG were hybridized with labeled sense or 
antisense RNA probes generated from PCR product using in vitro 
transcription.    Sections on slides were first treated with 0.2N HCl for 10 
minutes, washed with 1XPBS, treated with 20 mg/ml proteinase K at 
37℃ for 5 minutes, acetylated with 0.25% acetic acid and 0.1M 
triethanolamine (TEA) for 10 minutes, postfixed with 4% 
paraformaldehyde at 4℃ for 10 minutes. After washed with 1X PBS, 
slides were then prehybridized at 60℃ for 2 hours. After prehybridization 
buffer removed, slideswere incubated with probe (400 ng/ml) in 
hybridization buffer (100% formamide 5 ml, 20X SSC 2.5 ml, 50% 
Dextrane sulphate 2 ml, 20% SDS 0.5 ml, PVP (poly-vinylpyroline) 0.1 
gm, 100X Denhardt’s solution 0.1 ml, 10 mg/ml Salmon sperm 0.1 ml) at 
  2060℃ overnight. After wash with 2X SSC at 42℃, 1X SSC (plus 0.1% 
Tween 20) at 37℃, 0.2X SSC (plus 0.1% Tween 20) at room temperature 
for 10 minutes each for twice. Slides were then washed with buffer 1 (100 
mM Tris-HCl,150 mM NaCl，pH7.5 ) for 5 minutes, two times, then 
blocked in 1% blocking reagent for 30 minutes. After washed with buffer 
1 for 5 minutes, sections were then hybridized with anti-DIG antibody 
(1:8000 diluted with 1% blocking reagent) at room temperature for 2 
hours. After wash with buffer1 for 5 minutes for two times, slides were 
then washed with buffer 2 (100 mM Tris-HCl, 100 mM NaCl, 50 mM 
MgCl2, pH9.5) for 10 minutes. Color reactions were carried out in buffer 
2, using nitroblue tetrazolium chloride (NBT) and 
5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Roche) as substrates, 
until appropriate signals were founded. Slides were washed with buffer 2 
for 10 minutes, counterstained with 1% methyl green for 1 second, rinsed 
by RNase-free water, air dry at 37℃ overnight, and cover slipped for 
light microscopy. 
 
Establishment of ATXN8OS inducible construct   
 
    ATXN8OS cDNAs with 22 or 150 CTG repeat fused with Flag tag 
were digested from transgenic mouse construct (Chen, 2006) by 
restriction NotI and SalI,  and then sub-cloned into NotI/SalI site of 
pEGSH vector. The completed constructs were shown in Fig. 2. 
 
  21Cell culture and transfection of PC12 cell 
 
PC12 cells, originally derived from rat adrenal gland 
pheochromocytoma, were maintained in poly-L-lysine-coated plates 
containing 85% RPMI 1640 media (GIBCO) supplemented with 10% 
horse serum, 5% fetal bovine serum, 1% penicillin/streptomycin, 2 mM 
L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l D-glucose, 1 M HEPES, 
and 1 mM sodium pyruvate, and incubated in 5% CO2，37  incubator. ℃   
Cells were seeded on poly-L-lysine coated plate overnight prior to 
transient transfection. PC12 cells were transfected using Lipofectamine 
2000 as the manufacturer’s instructions (Invitrogen). Clonal 
PC12/pERV3 cells were established by transfected with 2 µg pEGSH 
vector DNA (Wang, 2007). or pEGSH/ ATXN8OS with different (CTG) 
repeat length respectively 6 μl lipofectamine 2000 and 600 μl RPMI-1640 
(without serum), then pipeting mixed well, and incubated for 20 minutes 
at room temperature. At DNA-lipofectamine 2000 complexs formation, 
then add 2400 μl RPMI-1640 (without serum) mixed well, then added 
onto 3-cm dish which PC12/pERV3 cells were already cultured last night. 
After transfection, we utilized 20 mg/ml G418 for pERV3 cell selection 
and 10 mg/ml hygromycin B for pEGSH/ATXN8OS cell selection. 
 
Nerve Growth Factor (NGF) treatment of PC12 cells 
 
  The PC12 cells were plated at a density of 10
4 cells/cm
2 and 
allowed to adhere overnight, and the medium was replaced with RPMI 
  22medium supplemented with 0.5% serum medium and 50 ng/ml NGF to 
induce neurites sprouting for 48 hours. 
 
MTT assay 
 
    MTT assay is based on the ability of a mitochondrial 
dehydrogenase enzyme from viable cells to cleave the tetrazolium rings 
of the pale yellow MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) and form a dark blue formazan crystals which is 
largely impermeable to cell membranes, thus resulting in its accumulation 
within healthy cells. We first added 0.5 mg/ml MTT into cells. After 2 
hours of incubation in 37℃, we then dissolved formazan crystals with 
dimethyl sulfoxide (DMSO), measured OD570 values with a multiwell 
scanning spectrophotometer (Bio-Tek Microplate autoreader EL311). 
Through MTT assay, we evaluated the survival rate of cells. 
 
Immunocytochemistry (ICC) 
 
Differentiated PC12 cells grown on 6-cm culture dish were fixed in 
cold 4% paraformadehyde solution for 10 minutes at room temperature. 
After washes with 1X PBST (0.2% Tween-20 included) four times, cells 
were permeabilized with 0.5% Triton X-100 in PBS for 5 minutes, 
followed by washing three times. The non-specific protein binding sites 
will be blocked with 5% fetal bovine serum (FBS) for 2-4 hours, the cells 
were then incubated overnight in 4  with primary ATXN8OS ℃ -ORF1 
  23anti-serum (1:200), which was diluted with 5% FBS solution. After four 
times washing with 1X PBST for 10 minutes each, cells were incubated 
with anti-rabbit secondary antibody (green fluorescence, Alex Fluor® 
488 Donkey anti-mouse IgG) for 1 hour at room temperature and light 
protection. The cells were then washed with 1X PBST and counterstained 
with 4', 6-diamidino-2-phenylindole (DAPI, sigma) for 3 minutes, and 
removed DAPI then add 1X PBS into dish. The stain cells were observed 
with Leica microscope.   
 
  24Results 
 
Generation and characterization of inducible ATXN8OS cell lines   
The system was previously established in our labwith a Complete 
Control® Inducible Mammalian Expression System by transfection of 
pERV3 vector into PC12 cells (Wang, 2007).  We further expressed 
ATXN8OS/22R, and ATXN8OS/150R in this system (Fig. 1). After treated 
nerve growth factor (NGF), PC12 cell was differentiated to a neuron-like 
cell, then we added 5 µM PonA, ATXN8OS expression will be induced. 
Expression plasmids were constructed by ATXN8OS cDNAs with 22 
or 150 CTG repeat fused to Flag. The constructs were then transfected 
into PC12/pERV3 cells by lipofectamine 2000 (invitrogen). The 
ATXN8OS cDNAs were digested from transgenic mouse constructs (Chen, 
2006) with NotI and SalI, and then sub-cloned into pEGSH vector. The 
completed constructs were shown in Fig. 2. 
  In order to selected stable line, PC12/pERV3 cells with pEGSH 
vector, pEGSH/ATXN8OS/22R, or pEGSH/ATXN8OS/150R constructs, 
were selected by 20 mg/ml G418 and 10 mg/ml hygromycin for two 
weeks. stable cell lineswere induced by 5 µM of PonA for 24 and 48 
hours And toal RNAs were isolated for RT-PCR assay to identify the 
expression of ATXN8OS transcripts (Fig. 3).   
 
Identification of ATXN8OS-ORF1 expression by western blot 
It was previously reported that no coding open reading frame (ORF) 
in ATXN8OS was identified (Koob et al., 1999), however, three small 
  25cap-independent IRESmediated-ORFs were noted, ORF1, 102 amino 
acids, ORF2, and ORF3, 41 amino acids including the polyCUG-encoded 
polyleucine. By western blot assay, we used ATXN8OS-ORF1 anti-serum 
(kindly provided by Dr. Lee-Chen, NTNU), and detected a possible 
ORF1 band of around 24 kDa from cells with constructs 
pEGSH/ATXN8OS/22R and pEGSH/ATXN8OS/150R (Fig. 4).   
 
Viability test of inducible ATXN8OS cell lines   
MTT assay results reveal  stable cells with ATXN8OS-150R show 
significantly reduced cell number after PonA induction for 48 hours and 
72 hours. However, cells with pEGSH vector or ATXN8OS-22R 
overexpression showed no significant difference after PonA treatment 
(Fig. 5). 
 
Generation of inducible PC12/ATXN8OS clonal cell lines 
In order to obtain a more uniform expression and phenotypes of cells, 
we selected clonal cells from stable cell population. Two individual clonal 
cell lines were selected from stables cells with pEGSH/ATXN8OS/22R 
(lines 2 and 12) and pEGSH/ATXN8OS/150R (lines 1 and 4) by RT-PCR 
assay (Fig. 6). 
 
Viability test of ATXN8OS inducible clonal cell lines   
To investigate the effect of ATXN8OS expansion overexpression in 
PC12 cells, MTT assay was conducted and the results reveal clonal cells 
with  ATXN8OS-150R (line-1) show significantly reduced cell number 
after PonA induction for 72 hours, cells with ATXN8OS-150R (line-4) 
  26show significantly reduced cell number after PonA induction for both 48 
and 72 hours, and cells with pEGSH vector show significantly reduced 
cell number after PonA induction for 24 hours. However, cells with 
ATXN8OS-22R overexpression showed no significant difference after 
PonA treatment (Fig. 7). 
 
Identification of ATXN8OS-ORF1 expression in clonal cells by 
Immunocytochemistry (ICC) 
ICC analysis with ATXN8OS-ORF1 anti-serum, showed that after 48 
hours NGF treatment and then PonA induction, clonal ATXN8OS-150R 
(lines 1 and 4) and ATXN8OS-22R (lines 2 and 12) cells have stronger 
staining than non- induced cells (Fig. 8). 
 
Morphology of ATXN8OS inducible clonal cell lines 
To investigate the effect of ATXN8OS expansion overexpression in 
PC12 cells, we characterized cell morphological change during the PonA 
induction for 48 hours. We examined the cell morphology during 
differentiation (after NGF treatment for 48 hours) because our 
preliminary MTT assay results reveal significant difference between cells 
with vector only and clonal cell lines with ATXN8OS-150R under 
differentiation states (Figs. 5 and 7). In order to identify the morphology 
of these cells, we measured the neurite length and numbers of these cells 
after PonA induction 48 hours during NGF treatment. The measurement 
was conducted in ten individual areas of each culture dish. Both neurite 
length and numbers of cells with ATXN8OS-150R are significant 
decreased compared to cells with ATXN8OS-22R and vector only (Figs. 
  2710 and 11). In addition, we also found ATXN8OS-150R cell neurites are 
thinner and weaker than ATXN8OS-22R and vector only cells (Fig. 9). 
  
Generation and characterization of ATXN8OS transgenic mouse 
To generate transgenic mice expressing human ATXN8OS gene. 
Human ATXN8OS cDNA with D, C2, C1, B and A, bearing normal 
CTG/CTA repeat (22R) or expanded CTG/CTA repeat (150R) fused to 
flag and EGFP (kindly provided by Dr. Lee-Chen, NTNU), were 
subcloned behind the NSE promoter (Fig. 12A). The transgen fragments 
were released from the constructs by restriction enzyme MluІ and the 
resulted 4.1- and 4.6-kb fragments were used for microinjection to 
generate transgenic mice (Fig. 12B).   
 
ATXN8OS transgene caused the Purkinje cell loss in transgenic mice 
To observe the transgene effect in ATXN8OS150R transgenic mice, 
we used IHC analysis with calbindin D28k antibody (sigma) to assess the 
numbers and pattern of the cerebellar Purkinje cells.     
First, we found transgenic mouse cerebellum at the age of 7 weeks 
have mild loss of Purkinje cells (Fig. 13), and at the age of 64 weeks, 
Purkinje cell loss is significant (Fig. 14). 
At the age of 76 weeks, we found not only the reduced number of 
Purkinje cells, but also the progress cell death. We also quantified the 
Purkinje cells at the stage (n=3), and our results indicate Purkinje cell loss 
significantly in the mice at age of 76 weeks (Fig. 15).   
 
ATXN8OS cause the neuronal loss in transgenic mouse cerebellum 
  28To understand the effect of ATXN8OS on the other neurons of 
cerebellum, we used IHC analysis with NeuN antibody to assess the 
numbers of the neuron cells. At the age of 76 weeks, we observed neuron 
loss in deep cerebellar nuclei (DCN) of transgenic mice (Fig. 16). 
We also used microtubule associated protein-2 (MAP2) antibody to 
exam the cerebellum of transgenic mice, at 76 weeks, we found DCN of 
transgenic mouse have more significant signal of MAP2 (Fig. 17).   
There is no difference observed in GFAP positive astrocyte staining 
between transgenic and wild type mice (Fig. 18). 
 
ATXN8OS encodes translable ORF3 
In order to exam the existence of ORF3 in ATXN8OS transgenic mice, 
we used antibody against Flag-tag to detect ORF-3-flag fusion protein in 
transgenic mice. In DCN of transgenic mice, we did observed stronger 
Flag signal than that in DCN of wild type mice (Fig. 19). 
 
Identification neuron markers in ATXN8OS-150R mouse cerebella by 
western blot analyses 
Our preliminary IHC data showed significant difference between 
heterozygous transgenic and wild type mice, we performed western blot 
to confirm these data. We used three antibodies to detect neuron status for 
4 month-old mice. First, we used NeuN to detect neuronal nuclei, is 
significant difference between transgenic and wild type mice (upper panel, 
Fig. 20). Second, we used calbindin to detect Purkinje cells, we also 
cannot founded significant difference (middle panel, Fig 20). Finally, we 
used GFAP to detect glial cells, astrocytes, and gliosis, TG2 and TG3 of 
  29ATXN8OS-150R transgenic mice showed reduced signals compared to 
wild type (lower panel, Fig. 20). 
Since SCA8 is a late-onset disease, so we conducted the same 
analysis on 64 week-old mice. We found TG1 showed reduced staining of 
calbindin and NeuN, and increased GFAP staining (Fig. 23). 
      
Identification of apoptosis marker in mouse cerebella by western blot 
analyses 
   O u r   preliminary western blot data indicate neuron loss and gliosis  
occurred in some transgenic mice (Fig. 23), we thus used three widely 
used antibodies (BAX, Bcl-2 and Cyt c) to detect apoptosis of these 
transgenic mice. When mice were 4-month-old, some transgenic mice 
showed significantly increased staining of Bcl-2, BAX and cyt c (Fig. 21). 
However, when mice were 64-weeks-old, no significant Bcl-2 staining 
was identified (Fig. 24).         
 
Identification of ATXN8OS-ORF1 expression in mouse cerebellum by 
western blot analysis 
We used ATXN8OS-ORF1 anti-serum (kindly provided by Dr. 
Lee-Chen, NTNU) and detected a possible ORF1 band around 24 kDa in 
cells with constructs pEGSH/ATXN8OS/22R and 
pEGSH/ATXN8OS/150R (Fig. 4), and mouse cerebella (Fig. 22).   
 
Different phenotypes between 150R transgenic littermates 
Some transgenic mice have more obvious phenotypes, showing small 
size, weakness and kyphosis (curvature of the spine) (Figs. 25A and 25B). 
  30Clasping phenotype was also observed with all feet holding together 
when the mouse tail was suspended (Fig. 25C). 
And the end of the disease, we found some of adult male mice 
showed priapism phenotype (Fig. 25D). We thus checked testis histology 
to understand morphology of germ cells. The result of Nissl staining 
reveals that transgenic mouse sperm numbers are less than that of wild 
type, and germ cells with abnormal morphology were also identified in 
transgenic mouse testis (Fig. 26). 
 
Behavior characterization of heterozygous transgenic mice by 
performance on the accelerating rotarod 
To exam the motor performance and coordination activity, we tested 
mice on the rotarod with speed from 2 to 20 rpm during first 5 minutes, 
and maintained at 20 rpm for another 5 minutes, and to record their 
latency in the rod. Our results showed that ATXN8OS-150R transgenic 
mice could stayed longer time on rotarod than wild type littermates at 12 
weeks old of age (Fig. 27). We further modified the rotarod program from 
2 to 40 rpm for the first 5 minutes and maintain at 40 rpm for another 5 
minutes and observed that ATXN8OS-150R mice still could stay longer 
on rotarod than wild type littermates at 32, 36 and 40 weeks old of age 
(Fig. 28). 
 
Locomotor activity of heterozygous transgenic mice 
Locomotor activity is good preliminary tests to determine motor 
deficits and exploratory, as assessed in the open field. From the results of 
locomotor analysis of 64-week-old mice, we found no significant 
  31difference between heterozygous transgenic mice and wild type mice in 
distance moved, velocity and rearing frequency (Fig. 29). 
 
Behavior characterization of homozygous transgenic mice by 
performance on the rotarod 
  In order to generate homozygous mice, we used semi-quantative 
PCR to identify homozygous mice from heterozygous mice. We obtained 
three homozygous mice further breeding of more homozygous mice for 
behavior test (Fig. 30).   
To exam the motor performance and coordination activity, we tested 
mice on the rotarod with fixed 25 rpm speed for 3 minutes, and to record 
their latency in the rod. During the 4-month period, we observed that 
homozygous mice showed shorter latency on rotarod than wild type mice 
(Fig. 31). And the behavior results were not affected by mouse body 
weight because there was no significant weight difference between 
transgene and wild type mice (Fig. 31).     
 
Locomotor activity of homozygous transgenic mice 
At 8, 14 and 22 week-old, mouse locomotor activity were 
characterized and the results showed homozygous mice moved less 
distance than wild type mice (Fig. 32). In addition, significant difference 
in average velocity was also identified between homozygous and wild 
type mice at 8, 14 and 22 weeks old, with ATXN8OS-150R homozygous 
mice have a slower velocity (Fig. 32). At 8 and 14 week-old, the rearing 
frequency were higher in homozygous mice than wild type mice, however, 
the result was reversed at 22 weeks old (Fig. 32). 
  32Establishment of ATXN8OS transgenic mice in B6 genetic 
background 
In order to generate ATXN8OS-22R normal repeat transgenic mice 
and more lines of ATXN8OS-150R transgenic mice for further 
characterization of the effect of long CTG repeat ATXN8OS gene, we 
have used the same transgenic constructs for pronuclear microinjection 
with the help of Core facility of Institute of Molecular Biology, Academia 
Sinica. From RT-PCR result, we chose three lines (44, 45 and 46) from 
ATXN8OS-22R and five lines (29, 30, 33, 34 and 38) from 
ATXN8OS-150R F1 transgenic mice for further breeding and analyses. 
We assessed the expression of transgene in the cerebellum by RT-PCR 
(Fig.  33).         
ATXN8OS expression was identified in several regions of the 
cerebellum of ATXN8OS-22R mouse by in situ hybridization, such as 
cerebellar lobe (Fig. 34J), the deep cerebellar nuclei (Fig. 34K), and the 
brain stem (Fig. 34L). In the cerebellar lobe, significant expression of 
ATXN8OS mRNA was observed in the molecular layer and Purkinje cell 
(Fig. 34J).   
ATXN8OS expression was also found in the similar regions of the 
cerebellum of ATXN8OS-150R mouse, such as the cerebellar lobe (Fig. 
35K), the deep cerebellar nuclei (Fig. 35L), and the brain stem (Fig. 36G, 
36H). In the cerebellar lobe, significant expression of ATXN8OS mRNA 
was observed in the molecular layer and Purkinje cell (Fig. 35K). 
  33Discussion 
 
Cell model 
Inducible system of PC12/pERV3 cells with pEGSH vector was 
previously established in our lab (Wang, 2007). We used the system to 
transfect construct pEGSH/ATXN8OS/22R or pEGSH/ATXN8OS/150R, 
then selected by hygromycin and G418. After pEGSH/ATXN8OS/22R 
and pEGSH/ATXN8OS/150R was induced by PonA, we can detect 
ATXN8OS transcripts expression in stable and clonal cell lines. 
In previous report, ATXN8OS contains six exons and is a non-coding 
CUG expanded RNA (Koob et al., 1999). From our result, we also found 
ATXN8OS was transcribed successfully in our inducible system. 
ATXN8OS is characterized by RT-PCR with repeat expansion segments 
in untranslated regions (UTRs). These RNAs may recruit splicing factors 
and transcription factors, and resulting in ribonucleoprotein aggregates 
(RNA foci) (La Spada et al., 2004). The formation of RNA foci might 
mis-regulation of splicing signaling or regulatory pathways. The effect of 
the repeats on splicing mis-regulation requires an intact CUGBP1-binding 
site (CUG-BP1 response element) within affected pre-mRNAs (Ho et al., 
2005). In our result, we observed growth rate of  cells with 
ATXN8OS-150R is less than cells with ATXN8OS-22R or vector only\, 
suggesting CTG expansion exert more cytotoxicity than normal repeat, 
and RNA foci maybe regulate growth factor, make it mis-regulation to 
cause growth rate slowly. In addition, other report indicated when cells 
with CTG-250 treated with NGF, cytotoxicity was increased in the cells. 
  34And the CTG repeat bearing mRNA showed cis-effects through the 
reporter gene and neuronal death after cell differentiation in vitro (Furuya 
et al., 2005). From our MTT assay results, we found viability in cells with 
long CTG expansion is reduced compared to cells with normal repeat 
after  NGF  treatment.    
ATXN8OS has been proven to be an intact transcript which has six 
exons and alternative polyadenylation sites, but ATXN8OS revealed no 
translatable ORFs existing of any splice isoforms (Nemes et al., 2000). 
Initiation of translation often depends on 5’ m
7G cap, which interact to 
43S ribosome with the cap binding protein eIF4E (Sonenberg, 1994). And 
ATXN8OS transcripts 5’UTR containing a G/C rich region which maybe 
serve as a recognition site of trans interacting factor (Nemes et al., 2000). 
In recently report, ATXN8OS was suggested to have IRES activity, and 
revealed the existence of three small ORFs (Lin, 2007). In our research, 
we used ecdysone regulatory inducible system to overexpress 
ATXN8OS/22R and ATXN8OS/150R in PC12 cell line. Expression ORF1 
protein with different length CTG repeat were identified after cells were 
induction by PonA for 48 hours. And we used ICC to confirm this result, 
Cells were treated with NGF to induced differentiation for 48 hours, and 
than induce with PonA for 48 hours, we can observe ORF1 expressed in 
whole cell body.   
Although both cells with ATXN8OS/22R and ATXN8OS/150R have 
ORF1 expression, we suggest ORF1 may regulate ATXN8OS toxicity, 
only ORF1 in cells with expanded repeats will induce its toxicity. 
The expanded CTG90 repeats was reported to inhibit neuronal 
differentiation in a PC12 cell line (Quintero-Mora et al., 2002). Our result 
  35also showed that ATXN8OS/150R has reduced differentiation activity 
compared to cells with normal repeats or vector.     
In summary, we have established the cell system in which 
ATXN8OS/22R and ATXN8OS/150R can be induced expressed. Both the 
cell viability and neuronal differentiation of ATXN8OS/150R were 
reduced than control cells with short repeats or vector only. These results 
suggest that RNA and/or ORF1 expression from expanded CTG repeats 
of  ATXN8OS make the cells more vulnerable than cells with normal 
repeats. This model provides an in vitro system might be useful for the 
SCA8 therapeutic design in the future.   
 
Mouse model 
Transgenic mice expressing ATXN8OS-150R transcripts were 
characterized by behavior testing and IHC to exploit the pathogenesis and 
to understand whether the expanded trinucleotide repeat mutations of 
ATXN8OS can involve gain of function mechanism as myotonic 
dystrophy (DM1) (Gatchel and Zoghbi, 2005). 
IHC analysis can provide a sensitive method in examing the 
morphology of cerebellum. Calbindin expression was high in Purkinje 
cell dendrite and cell body in the molecular layer; it’s also a marker of 
cerebellar toxicity (Haworth et al., 2006). In our result, with calbindin 
immunostaining, we found Purkinje cell loss and degeneration severely in 
the cerebella of ATXN8OS-150R transgenic mice. It has been proved that 
Purkinje cell loss is a major contributing factor to motor performance 
dysfunction in P/Q channel-related ataxias (Walter et al., 2006).   
  36In our IHC studies, we using NeuN antibody to observe the 
functional changes in the cerebellum of our ATXN8OS-150R mice and 
found neuronal cell loss in DCN. In addition, in the DCN we 
characterized the MAP2 (microtubule-associated protein 2) expression, 
MAP2 familiy is an abundant group of cytoskeletal component with 
functions including stabilization of microtubule, the regulation of 
organelle transport within axons and dendrites, and regulation of some 
proteins about signal transduction (Sanchez et al., 2000). In our study, we 
found stronger staining of MAP2 in DCN of transgenic mice, which 
reflect cerebellar ataxia may in part be initiated as a consequence of 
increase DCN (deep cerebellar nuclei) excitability secondary to loss of 
inhibitory input from Purkinje cell that frequently degenerate or alter 
function (Grusser-Cornehls and Baurle, 2001). These results represent our 
transgenic DCN is under hyperexcitability which maybe secondary to 
loss  of  Purkinje  cells.        
In our westren blot studies, among the three 64-week-old transgenic 
mice, we can observed one mouse has neuronal loss (calbindin and NeuN 
decreased) and gliosis (GFAP increased), however, these results were not 
found at 4 month-old mice, which suggests a late-onset disease of our 
mouse model with neuronal-pathogenesis detected at older age.   
Apoptosis, also known as programmed cell death, is an active process 
of cell death which controls cell numbers in a variety of tissues during 
development and adult life (Raff et al., 1993). The Bcl-2 family of 
proteins plays a central role in regulating apoptosis. It has been well 
established that these proteins function at the mitochondria to prevent or 
promote the release of apoptogenic factors such as cyt c. Bcl-2, a major 
  37anti-apoptotic protein located primarily in the outer mitochondrial 
membrane, inhibits apoptosis by preventing cyt c release from the 
mitochondria and inhibiting caspase activation, while Bax, which shares 
extensive amino acid homology with Bcl-2, acts as a functional 
antagonist to Bcl-2 (Buchholz et al., 2003). The neuronal cell loss of our 
transgenic mice maybe through a process of apoptosis. From western 
bloting results, we observed Bcl-2, BAX and cyt c were increased in 
some mouse cerebella at both 16- and 64-weeks-old stages. Bcl-2 during 
development can protect neurons from both physiological and induced 
cell death, represent in development stage Bcl-2 maybe involved in 
protection of neurons during the period in which half of the neurons are 
undergo apoptosis (Farlie et al., 1995). Whether the apoptotic prpcess 
indeed occurred in our transgenic mouse model will need further 
characterization of expression of other apoptotic effectors, eg. caspase-3. 
Rota-rod assay is the most widely used test to assess coordination and 
overall motor function in rodents. This test is affected by experimental 
damage to the basal ganglia and cerebellum as well as genetic 
manipulations and drugs that effect motor function. This test can be 
carried out as a single measure or multiple times to determine cerebellar 
learning. In our study, there is no significant difference in the rotarod 
performance between heterozygous and wild-type mice, suggesting the 
motor activity and coordination of the heterozygous mice was sustained 
at the testing stages. A later onset might be identified in these 
heterozygous mice if we continually conduct the task. In order to generate 
mice with more severe phenotypes, we set up heterozygous mouse 
breeding to obtain homozygous mice. The rota-rod assay of the young 
  38homozygous mice reveals that the latency to fall in homozygous mouse 
was even shorter than that in wild type control animals. We anticipate to 
find a poorer performance in homozygous mice in later stage.   
In the locomotor activity examination, the total of distance, average 
velocity and rearing frequency are measured. Our test results indicated 
that total distance and average velocity in the homozygous transgenic 
mice are significantly less than that in wild type mice, representing our 
ATXN8OS-150R homozygous transgenic mice have motor activity 
deficits. The test is sensitive to motor dysfunction as well as hippocampal 
and basal ganglia damage. Further pathological examination of these area 
should be conducted for elucidation of this question. 
About progressive neurological phenotype of our transgenic mouse 
model, we founded some mice with severe phenotypes, such as small size, 
curvature of the spine and priapism. These phenotypes are similar to 
BAC-ATXN8OS transgenic mice (Moseley et al., 2006). Priapsim, among 
these progressive neurological phenotype, was happened at the end of 
disease, which may cause by spinal cord curvature and the blood back-up 
to make hematoma of the end. 
Reduced penetrance is associated with SCA8 patients. For our 
transgenic mice, whether the expanded repeat bearing ATXN8OS reduce 
transcription efficiency or unstable IRES activity making severe 
phenotypes occurred in only some of the transgenic mice remains further 
study.  
Our  ATXN8OS transgenic mouse model demonstrates the 
morphology effects caused by the ATXN8OS expansion and provides a 
  39system for further characterizing other trinucleotide disorders, such as 
myotonic dystrophy1 and Huntington disease like 2. 
For a more reasonable study, we have already established ATXN8OS 
transgenic mice in B6 genetic background. With comparison between 
mice bearing normal repeats (ATXN8OS-22R) and expanded repeats 
(ATXN8OS-150R). Our research results can provide more insight of the 
pathogenesis of SCA8 or other neurodegenerative diseases. 
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  49Table 1. Primer sequences and annealing temperature for 
PCR reactions in this study 
 
Function Primer  Sequence 
Annealing 
temp. 
pEGSH-F  5'-CAACTGCAACTACTGAAATCTGCC -3’ 
 
Cell 
genotyping 
 
pEGSH-R  5'-AGCAATTAACCCTCACTAAAGGGC -3’ 
54℃ 
C2-F  5'-CACACATAGTAGAAGGCAGAAGGGC-3’  Cell 
RT-PCR  C1-R  5'-CTTGTTCCCGCTTGACTCTGAG-3’ 
54℃ 
NSE-F  5’-AATAAGGAGACGCCTGCTTCCCTC-3’  Mouse 
genotyping  SCA8-R  5’-CATGTCAGGCTCTGGGCGAAAAG-3’ 
58-54.5℃ 
SCA8-F1  5’-TTGAAGATTGCCTTTTCTGACTCCC-3’  Mouse 
RT-PCR  EGFP-R  5’-ACTCCAGCAGGACCATGTG-3’ 
58.5℃ 
β-actin-F  5’-ATGGATGACGATATCGCT-3’  Internal 
control  β-actin-R  5’-ATGAGGTAGTCTGTCAGGT-3’ 
54℃ 
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Table 2. Primer sequences and annealing temperature for 
generation of probles for in situ hybridization 
 
Gene Primer  Sequence 
Annealing 
temp. 
Flag-F  5'-TGACTACAAAGACGATGACG-3’   
ATXN8OS 
 
EGFP(1624
-1607)-R 
5'-CTTGAAGAAGATGGTGCG-3’ 
54℃ 
Calbindin-F  5'-GAGAACTATTCAGGATGTGTGG-3’  Calbindin 
(positive 
control) 
Calbindin-R  5'-TTTGGTGCTTCAGAGGCAG -3’ 
56℃ 
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Table 3. Clonal cell line established after selection 
 
line  150R-1 150R-2 150R-3 150R-4 150R-5 
Genotyping  + - - + + 
RNA level  +  -  - ++ - 
 
 
line 150R-6  150R-7  150R-8    
Genotyping  + - -     
RNA level  - - -    
 
 
line  22R-2 22R-3 22R-4 22R-5 22R-6 
Genotyping  + - - + + 
RNA level  +++ -  -  leaky  leaky 
 
 
line 22R-8  22R-9  22R-11  22R-12  
Genotyping  - + - +  
RNA level  - leaky -  ++   
 
- : negative result or No RNA expression   
 
+: positive result or RNA expression level 
 
 
 
 
 
 
 
 
 
 
  52Table 4. ATXN80S transgenic mouse lines selected by 
RT-PCR 
 
22R line  repeat number  RT 
4842 N  NA   
4843 N  - 
4844 N  +++ 
4845 N  +++ 
4846 N  +++ 
4847 N  NA   
4848 N  - 
4849 N  NA   
4850 N  - 
4851 N  NA   
4852 N  - 
4853 N  dead 
4854 N  NA   
 
150R line  repeat number  RT 
4829  N + C  +++ 
4830 SC  +++ 
4831  N + C  ++ 
4832  N + SC  - 
4833 N  +++ 
4834  N + C  +++ 
4835 N  ++ 
4836 N  ++ 
4837  N + C  + 
4838  N + SC  +++ 
 
NA: non- analyzed 
 
SC: Severe contraction; C: contraction; N: normal 
  
 
 
  53Table 5. Antibodies used for western blot analyses 
 
 
Antibody NeuN  GFAP  Calbindin 
Brand Chemicon  Chemicon  Sigma 
Clonal Monoclonal  Monoclonal Polyclonal 
Titer 1:2000  1:2000  1:2000 
Host Mouse  Mouse  Rabbit 
Mol. weight  46,48, & 66 kDa 51 kDa  28 kDa 
 
Antibody Cyt  c  Bcl-2  BAX 
Brand Santa  Cruz Sigma  BD   
Clonal Polyclonal  Monoclonal  Monoclonal 
Titer 1:1000  1:1000  1:1000 
Host Rabbit  Mouse  Mouse 
Mol. weight  12 kDa  26 kDa  24 kDa 
 
Antibody HSP70  ORF1 α-tubulin 
Brand  Stressgen  Provided by Dr. 
Lee’s lab   
Santa Cruz 
Clonal Monoclonal  Anti-serum  Monoclonal 
Titer 1:1000 1:200 1:800 
Host Mouse  Rabbit  Mouse   
Mol. weight  70 kDa  24 kDa  55 kDa 
 
Cyt c: Cytochrome c 
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Fig 1. Inducible expression of ATXN8OS in PC12 cells by using 
Complete Control® Inducible Mammalian Expression System 
(Stratagene).  
 
(A) In the absence of PonA (the inducer), the promoter is tightly 
repressed by corepressors. (B) When PonA binds to VgEcR, the 
corepressors are released, coactivators are recruited, and the complex 
becomes transcriptionally active. 
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Fig 2. Establishment of ATXN8OS inducible expression construct. 
 
(A) pEGSH/ATXN8OS construction. The cDNA fragments 
(ATXN8OS-22R and 150R) were subcloned into the MCS of pEGSH 
vector. (B) Restriction map of pEGSH/ATXN8OS constructn. Lane 1, 
pEGSH/ATXN8OS/22R uncut; Lane 2, pEGSH/ATXN8OS/150R uncut. 
Lane 3: pEGSH/ATXN8OS/22R  NotΙ/SalΙ digestion. Lane 4: 
pEGSH/ATXN8OS/150R NotΙ/SalΙ digestion. 
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Fig 3.    ATXN8OS expression induced by PonA in stable cell lines. 
 
Cell total RNAs were isolated from ATXN8OS-22R  and 
ATXN8OS-150R stable cells after induced with PonA for 24 hours and 48 
hours. RT-PCR analysis was conducted with specific primers designed 
for detecting the human ATXN8OS transcripts. The β-actin transcript was 
used as an internal control. 
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Fig 4. ATXN8OS-ORF1 expression induced by PonA in stable cell 
lines. 
 
Cell total proteins were isolated from ATXN8OS-22R  and 
ATXN8OS-150R stable cells after induced with PonA for 48 hours. 
Western blot analysis was conducted using ATXN8OS-ORF1 anti-serum. 
The arrow indicates ORF1. α-tubulin was used as an internal control. 
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Fig 5. Stable cell line with overexpressed ATXN8OS-150R is more 
vulnerable than those with ATXN8OS-22R and pEGSH vector. 
 
(A) Schematic diagram showing the schedule of treatment and MTT 
assays with stable cell lines. Cell density was analyzed by MTT assays at 
24 hours, 48 hours and 72 hours after PonA induction which following a 
48 hours NGF treatment. (B) Cells transfected with pEGSH vector only 
showed no significant difference with PonA induction. (C) Cells with 
ATXN8OS-22R overexpression showed no significant difference with or 
without PonA induction. (D) Cell with ATXN8OS-150R overexpression 
show significant reduced cell numbers after PonA induction for 48 and 72 
hours. (*, P < 0.05  ； **, P < 0.01； ***, P < 0.005). 
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Fig 6. ATXN8OS expression induced by PonA in PC12 clonal cell 
lines. 
 
Cell total RNAs were isolated from ATXN8OS-22R  and 
ATXN8OS-150R clonal cells after induced with PonA for 24 hours. 
RT-PCR analysis was conducted with specific primers designed for 
detecting the human ATXN8OS transcripts. β-actin transcript was used as 
an internal control. (A) Expression of ATXN8OS-22R in clonal cell 
analyses by RT-PCR. (B) Expression of ATXN8OS-150R in clonal cell 
analyses by RT-PCR. 
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Fig 7. Clonal cell line with overexpressed ATXN8OS-150R is more 
vulnerable than those with ATXN8OS-22R and pEGSH vector. 
 
(A) Schematic diagram showing the schedule of treatment and MTT 
assays with stable cell lines. Cell density was analyzed by MTT assays at 
24 hours, 48 hours and 72 hours after PonA induction which following a 
48 hours NGF treatment. (B) Cells transfected with pEGSH vector only 
show significant reduced cell numbers after PonA induction for 24 hours. 
(C) Cells with ATXN8OS-22R-2 overexpression showed no significant 
difference with PonA induction. (D) Cells with ATXN8OS-22R-12 
overexpression showed no significant difference with PonA induction. (E) 
Cell with ATXN8OS-150R-1 overexpression show significant reduced cell 
numbers after PonA induction for 72 hours. (F) Cell with 
ATXN8OS-150R-1 overexpression show significant reduced cell numbers 
after PonA induction for 48 and 72 hours. (*, P < 0.05  ； **, P < 0.01； 
***, P < 0.005). 
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Fig 8. ATXN8OS-ORF1 expression in differentiated PC12 cell after 
PonA induced for 48 hours. 
ATXN8OS-22R-2 (A) and ATXN8OS-22R-12 (B) clonal cells, in upper 
panel, after 48 hours NGF treatment and PonA induced for 48 hours, 
showed ORF1 protein in the neuron-like status. Lower panel, cells 
without PonA induction. Scale bar = 10 µm.       
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ATXN8OS-150R-1 (C) and ATXN8OS-150R-4 (D) clonal cell, in upper 
panel, after 48 hours NGF treatment then PonA induced for 48 hours, 
induced cells showed ORF1 protein in the neuron-like status. In lower 
panel without PonA induction. Scale bar = 10 µm.     
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Fig 9. Expression of the ATXN8OS-150R inhibits neuronal outgrowth 
in the differentiated PC12 cells after PonA induced for 48 hours. 
 
Phase contrast photographs of representative fields, showing typical 
morphologies of PC12 cell after 48 hours treatment with NGF. Upper 
panel, after 48 hours NGF treatment but without PonA induction, 
neuronal outgrowth normaly, Lower panel, after NGF trratment and then 
PonA induction for 48 hours, ATXN8OS-150R clonal cell showed 
abnormal  morphology.   
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Fig 10. Expression of the ATXN8OS-150R reduced dendrite length in 
the differentiated PC12 cells after PonA inducion for 48 hours. 
 
We calculated length of neurite from each neuron in ten photographic 
field per culture dish. Asterisk denotes significant differences between 
non- induce and induce ATXN8OS-150R-1 and ATXN8OS-150R-4 
induced clonal cells. And there wereNo significant differences between 
vector only induced and induce ATXN8OS-150R-1 cells, and between 
vector only induced and induce ATXN8OS-150R-4 cells. (*, P < 0.05 ； 
**, P < 0.01； ***, P < 0.005). 
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Fig 11. Expression of the ATXN8OS-150R reduced neuronal numbers 
in the differentiated PC12 cells after PonA induction for 48 hours. 
 
We calculated numbers of neurite from each neuron in ten 
photographic field per culture dish. Asterisk denotes significant 
differences between non-induce and PonA-induce ATXN8OS-150R-4 
clonal cells. (*, P < 0.05  ； **, P < 0.01； ***, P < 0.005). 
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Fig 12. Establishment of ATXN8OS transgenic mice. 
 
(A) Schematic diagram of NSE-ATXN8OS-flag-EGFP constructs. The 
NSE promotor drives human ATXN8OS in-framed with flag-EGFP. (B) 
Restriction map of NSE-ATXN8OS-flag-EGFP constructs. Lane 1, 
NSE-ATXN8OS-22R-flag-EGFP construct with MluΙ digestion. The 4.1 
kb liner DNA fragment is for pronuclear microinjection. Lane 2, 
NSE-ATXN8OS-150R-flag-EGFP construct with MluΙ digestion. The 4.6 
kb liner DNA fragment is for pronuclear microinjection. 
[The construction was completed by Wei-Lun Chen (Chen, 2006)] 
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Fig 13. IHC analyses of ATXN8OS-150R mouse cerebella at 7 weeks. 
 
  The brown staining of wild type (A) and ATXN8OS-150R (B) cerebella 
showing the calbindin-immunoreactivity of Purkinje cells. In panels (C) 
and (D) are higher magnification of the framed areas of (A) and (B) in 
cerebellum lobe. Scale bar = 50 μm. 
 
 
 
  69 
 
 
 
Fig 14. IHC analyses of ATXN8OS-150R mouse cerebella at 64 weeks. 
 
  The brown staining of wild type mouse (A) and ATXN8OS-150R mouse 
(B) showing the calbindin-immunoreactivity of Purkinje cells. In panels 
(C) and (D) are higher magnification of the framed areas of (A) and (B) 
in cerebellum lobe. Scale bar = 50 μm. 
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Fig 15. IHC analyses and quantification of ATXN8OS-150R mouse 
cerebella at 76 weeks. 
  The brown staining of wild type mouse (A) and ATXN8OS-150R mouse 
(B) showing the calbindin-immunoreactivity of Purkinje cells. In panels 
(C) and (D) are higher magnification of the framed areas of (A) and (B) 
in cerebellum lobe. Scale bar = 50 μm. (**, P < 0.01). 
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Fig 16. IHC analyses of ATXN8OS-150R mouse cerebella at 76 weeks. 
 
  The brown staining of wild type mouse (A) and ATXN8OS-150R mouse 
(B) showing the NeuN-immunoreactivity of neuron cells. In panels (C) 
and (D) are higher magnification of (A) and (B) in DCN. Scale bar = 50 
μm. 
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Fig 17. IHC analyses of ATXN8OS-150R mouse cerebella at 76 weeks. 
 
  The brown staining of wild type mouse (A) and ATXN8OS-150R mouse 
(B) showing the MAP2-immunoreactivity of microtubule and 
cytoskeleton. In panels (C) and (D) are higher magnification of the 
framed areas of (A) and (B) in DCN. Scale bar = 50μm. 
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Fig 18. IHC analyses of ATXN8OS-150R mouse cerebella at 76 weeks. 
 
  The brown staining of wild type mouse (A) and ATXN8OS-150R 
mouse (B) showing the GFAP-immunoreactivity of glial cells and 
astrocytes. In panels (C) and (D) are higher magnification of the framed 
areas of (A) and (B) in cerebellum lobe. Scale bar = 50 μm. 
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Fig 19. IHC analyses of ATXN8OS-150R mouse cerebella at 76 weeks. 
 
  The brown staining of wild type mouse (A) and ATXN8OS-150R mouse 
(B) showing the Flag-immunoreactivity at cerebella. In panels (C) and (D) 
are higher magnification of the framed areas of (A) and (B) in DCN. 
Scale bar = 50 μm. 
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Fig 20. Western blot analysis of the ATXN8OS-150R mouse 
cerebellum at the age of 4 months.   
 
    NeuN antibody for detection of neuronal nuclei, Calbindin antibody 
can detect Purkinje cell, GFAP can detect astrocyte. (50 µg of protein 
loaded in each lane) 
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Fig 21. Western blot analysis of the ATXN8OS-150R mouse 
cerebellum at the age of 4 months. 
 
BAX, Bcl-2 and cyt c are apoptotic markers. We use these markers to 
detect whether apoptosis occurred in the neurons. In mouse TG3, BAX 
and cyt c expression are dramatically increased compared to the wild type. 
(50 µg of protein loaded in each lane) 
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Fig 22. ATXN8OS-ORF1 expression in the ATXN8OS-150R mouse 
cerebellum at the age of 4 months. 
 
Cerebellum total proteins were isolated from ATXN8OS-150R mouse at 
4 months. Western blot analysis was conducted using ATXN8OS-ORF1 
anti-serum. The arrow indicates ORF1. α-tubulin was used as an internal 
control. (50 µg of protein loaded in each lane) 
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Fig 23. Western blot analysis of the ATXN8OS-150R mouse 
cerebellum at the age of 64 weeks. 
 
    NeuN antibody can detect neuronal nuclei, Calbindin antibody can 
detect Purkinje cell, GFAP can detect astrocyte. Mouse TG1 shows GFAP 
expression dramatically increased compared with the wild type mouse. 
NeuN and calbindin expressions are dramatically decreased compared to 
the wild type mice. (50 µg of protein loaded in each lane) 
 
  79 
 
 
Fig 24. Western blot analysis of the ATXN8OS-150R mouse 
cerebellum at the age of 64 weeks. 
 
BAX, Bcl-2 and cyt c are apoptosis marker. We use there marker to 
detect neuron whether process apoptosis to pathway. TG1 BAX 
expression is dramatically increase compared with the wild type. (50 µg 
of protein loaded in each lane) 
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Fig 25. Morphological phenotypes of ATXN8OS-150R transgenic 
mice. 
(A) Heterogenous phenotypes of ATXN8OS-150R transgenic mice in 
the same litter at 5 weeks. (B) ATXN8OS-150R transgenic mouse size is 
smaller than it’s littermate. (C) The clasping phenotype of  one 
ATXN8OS-150R transgenic mouse. (D) Priapism (sustained penile 
erection) in one adult transgenic male mouse at the end stage of the 
disease. 
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Fig 26. Testis histology comparison between ATXN8OS-150R 
heterozygous mouse and wild type littermate. Scale bar = 50 μm. 
 
 
  82 
 
 
Fig 27. Results of Rotarod analysis of ATXN8OS-150R heterozygous 
and wild type mice at early stages. 
 
Latency is the amount of time animals were able to stay on the rotarod 
and analyses were conducted on the second day of the third trial of all 
three trials. The rod was accelerated from 2 to 20 rpm during a 10 
minutes period. Statistically significant differences are indicated by 
asterisks. Error bar represent the standard error of the mean (S.E.M.).   
(*, P < 0.05  ；  **, P < 0.01；  ***, P < 0.005). 
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Fig 28. Rotarod analysis of ATXN8OS-150R heterozygous mouse and 
wild type at later stages. 
 
Latency is the amount of time animals were able to stay on the rotarod 
and analyses the second day the third trial of all three trials. The rod was 
accelerated from 2 to 40 rpm during 10 minutes interval. Statistically 
significant differences are indicated by asterisks. Error bar represent the 
standard error of the mean (S.E.M.). (*, P < 0.05 ；  **, P < 0.01； ***,  P 
< 0.005). 
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Fig 29. Results of open-field locomotor activity test.   
 
The analysis was conducted when ATXN8OS-150R heterozygous mice 
and wild type littermates are 64 weeks old. Each mouse was put into a 30 
cm* 30 cm* 30 cm black box and detected by Etho-Vision video tracking 
system. There was no significantly different locomotor performance 
between wild type littermates and ATXN8OS-150R heterozygous mouse. 
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Fig 30. Result of semi-quantitative PCR for homozygous mouse 
identification. 
 
We used semi-quantitative PCR to distinguish heterozygous and 
homozygous mice by PCR product intensity. With ATXN8OS PCR 
product intensity is about 2 fold of other lanes was identified as 
homozygocity.  
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Fig 31. Results of rotarod analysis and weight curve of 
ATXN8OS-150R homozygous and wild type mice at different ages. 
 
Latency is the amount of time animals were able to stay on the rotarod. 
Results is the analyses of the third trials of two days. The rod was fixed at 
25 rpm for 3 minutes. Error bars represent the standard error of the mean 
(S.E.M.). 
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  There is no significant difference in body weight between 
ATXN8OS-150R homozygous and wild type mice after 12 weeks. 
Statistically significant differences are indicated by asterisks. (*, P < 
0.05  ； **, P < 0.01； ***, P < 0.005). 
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Fig 32. Results of open-field locomotor activity test. 
 
Each muse was put into a 30 cm* 30 cm* 30 cm black box and 
detected by Etho-Vision video tracking system for a 10 minutes period.  
There was significantly difference found in total distance between wild 
type and ATXN8OS-150R homozygous mice. (*, P < 0.05 ； **, P < 
0.01； ***, P < 0.005). 
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    There was significant difference in average velocity between wild 
type and ATXN8OS-150R homozygous mice. (*, P < 0.05 ； **, P < 
0.01； ***, P < 0.005). 
 
 
 
 
 
 
 
  90 
 
 
 
  
     There was significant difference in rearing frequency between wild 
type and ATXN8OS-150R homozygous mice at 14 weeks. (*, P < 0.05  ； 
**, P < 0.01； ***, P < 0.005). 
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Fig 33. ATXN8OS expression in different transgenic mouse lines 
established in C57B6 genetic background. 
 
Mouse total RNAs were isolated from ATXN8OS-22R  and 
ATXN8OS-150R mouse cerebella. RT-PCR analysis was conducted with 
specific primers designed for detecting the human ATXN8OS transcripts. 
β-actin  transcript was used as an internal control. (A) Expression of 
ATXN8OS transcripts in 22R mouse cerebella. (B) Expression of 
ATXN8OS transcripts in 150R mouse cerebella. 
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  93Fig 34. ATXN8OS mRNA expression in cerebella.   
 
In panels A, B, C, G, H and I, hybridizations were carried out with the 
ATXN8OS sense probes; in panels D, E, F, J, K and L, hybridizations 
were carried out with the ATXN8OS antisense probes. ATXN8OS sense 
probes does not stain in wild-type mouse cerebellar lobe (A), DCN (B) 
and brain stem (C).  (G) ATXN8OS sense probe does not stain in 
cerebellum lobe. (H) ATXN8OS sense probe does not stain in DCN. (I) 
ATXN8OS sense probes does not stain in brain stem. A, B and C 
cerebellum from wild type mouse. G, H and I cerebellum from 
ATXN8OS-22R transgenic mouse. Scale bar = 50 μm. 
 
In D, E, F, J, K and L, hybridizations were carried out with the 
ATXN8OS antisense probes. (D) ATXN8OS antisense probes does not 
stain in cerebellum lobe. (E) ATXN8OS antisense probes does not stain in 
DCN. (F) ATXN8OS antisense probes does not stain in brain stem. (J) 
ATXN8OS mRNA is detected in cerebellum lobe. (K) ATXN8OS mRNA 
is detected in DCN. (L) ATXN8OS mRNA is detected in brain stem. D, E 
and F cerebellum from wild type mouse. J, K and L cerebellum from 
ATXN8OS-22R transgenic mouse. Scale bar = 50 μm. 
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  95Fig 35. ATXN8OS mRNA expression in cerebellum. Transcripts are 
observed as a blue/purple stain.   
 
In panels A, B, C, G, H and I, hybridizations were carried out with the 
ATXN8OS sense probes. In panels (A) ATXN8OS sense probes does not 
stain in cerebellum. In panels (B) ATXN8OS sense probes does not stain 
in lobe. In panels (C) ATXN8OS sense probes does not stain in DCN. In 
panels (G) ATXN8OS sense probes does not stain in cerebellum. In panels 
(H)  ATXN8OS sense probes does not stain in lobe. In panels (I) 
ATXN8OS sense probes does not stain in DCN. A, B and C cerebellum 
from wild type mouse. G, H and I cerebellum from ATXN8OS-150R 
transgenic mouse. Scale bar = 50 μm. 
 
In panels D, E, F, J, K and L, hybridizations were carried out with the 
ATXN8OS antisense probes. In panels (D) ATXN8OS antisense probes 
does not stain in cerebellum. In panels (E) ATXN8OS antisense probes 
does not stain in lobe. In panels (F) ATXN8OS antisense probes does not 
stain in DCN. In panels (J) ATXN8OS mRNA is detected in cerebellum. 
In panels (K) ATXN8OS mRNA is detected in lobe. In panels (L) 
ATXN8OS mRNA is detected in DCN. D, E and F cerebellum from wild 
type mouse. J, K and L cerebellum from ATXN8OS-150R transgenic 
mouse. Scale bar = 50 μm. 
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  97Fig 36. ATXN8OS mRNA expression in cerebellum. Transcripts are 
observed as a blue/purple stain.   
 
In panels A, B, E, and F, hybridizations were carried out with the 
ATXN8OS sense probes. In panels (A) ATXN8OS sense probes does not 
stain in stem. In panels (B) ATXN8OS sense probes does not stain in stem. 
In panels (E) ATXN8OS sense probes does not stain in stem. In panels (F) 
ATXN8OS sense probes does not stain in stem. A, B cerebellum from wild 
type mouse. E, F cerebellum from ATXN8OS-150R transgenic mouse. 
Scale bar = 50 μm. 
 
In panels C, D, G, and H, hybridizations were carried out with the 
ATXN8OS antisense probes. In panels (C) ATXN8OS antisense probes 
does not stain in stem. In panels (D) ATXN8OS antisense probes does not 
stain in stem. In panels (G) ATXN8OS mRNA is detected in stem. In 
panels (H) ATXN8OS mRNA is detected in stem. C, D cerebellum from 
wild type mouse. G, H cerebellum from ATXN8OS-150R transgenic 
mouse. Scale bar = 50 μm. 
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Table 1. Gene location and products of SCAs 
 
Disease 
name 
Chromosome 
location 
Gene/product 
Normal 
range 
SCA1 6p22-23  ataxin-1(poly  Q)  6-36 
SCA2 12q24.1  ataxin-2(poly  Q)  15-31 
SCA3 14q32.1  ataxin-3(poly  Q)  12-40 
SCA6 19p13  α1A  Ca
2+ channel(poly Q)  4-16 
SCA7 3p21.1  ataxin-7(poly  Q)  4-19 
SCA8 13q21  Antisense  RNA  16-34 
SCA10 22q13.3  E46  10-22 
SCA12 5q31-33  PPP2R2B  6-29 
SCA17 6q27  TBP(poly  Q)  24-42 
                                       
                                      ( M o s e l e y   et al., 1998) 
 
Table 2. Clinical features of spinocerebellar ataxias 
 
                                           ( M a n t o   et al., 2005) 
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Table 3. Molecular Genetics of Autosomal Dominant Cerebellar 
Ataxias 
 
 
 
http://www.geneclinics.org/profiles/ataxias/  Gene review 
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Figure 1. Magnetic resonance imaging of the brain. 
 
The figures show progression of cerebellar atrophy (from left to right). 
                                       ( Z e m a n   et al., 2003) 
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Figure 2. Schematic diagram comparing various triplet expansion 
diseases.  
 
Transcripts known or initially shown to be expressed are depicted on 
the DNA strand 1. Newly discovered transcripts for SCA8 and DM1, 
which are expressed from the opposite strand, are depicted on the DNA 
strand 2. The height of triangles for respective diseases represents relative 
sizes of repeat expansions. Unfilled and blue boxes represent non-coding 
and protein-coding regions, respectively.     
  (Ikeda  et al., 2008) 
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Figure 3. Genomic organization of ATXN8OS, ATXN8, and KLHL1 in 
humans and mice. 
 
Comparison of the genomic organization of the overlapping ATXN8 
and ATXN8OS genes and 5’-region of the KLHL1 gene.   
                                        ( I k e d a   et al., 2008) 
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Figure 4. ATXN8OS RNA gain of function model. 
 
SCA8 (CTG9) transcripts normally regulate and bind to different 
RNA binding factors (pink circles and yellow stars). 
Overexpression of such transcripts could soak up the entire pool of 
such factors, effectively titrating them away from other proteins and/or 
RNA, and thereby compromising neuronal function.   
Expansions in CUG tract leads loss in binding to some of these 
factors (pink circles), and stronger association with some factors (yellow 
stars) as well as association with novel factors (red stars), ultimately 
leading to neurodegeneration. 
(Mutsuddi et al., 2005) 
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Figure 5. Plausible pathology of ATXN8OS 
 
These RNAs may recruit splicing factors (SF) and transcription 
factors (TF), ultimately resulting in the formation of large 
ribonucleoprotein aggregates (RNA foci), ATXN8OS maybe impact on 
other gene translation level.   
(LaFevre- Bernt et al., 2003 ; La Spada et al.,2004 ; Berke et al., 
2004；Wang et al., 2005) 
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Figure 6. ATXN8OS has three open reading frame. 
 
If ATXN8OS has IRES activity, ORF1, ORF2 and ORF3 could encodes 
protein.  
(Adapted from Lin, 2007) 
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